Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 19;11(20):3294. doi: 10.3390/cells11203294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of USP7 inhibitor on cell viability of chemoresistant TNBC. (A) The cell viability in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells treated with serial doses of USP7 inhibitor (GNE-6776) combined with doxorubicin or paclitaxel, respectively. (B) The cell viability of MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells treated with serial doses of USP7 inhibitor (GNE-6776). (C) Apoptotic levels in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under serial doses of GNE-6776 treatment, assessed performing Annexin V-dependent flow cytometry assays. (D) Analysis for apoptosis of GNE-6776 treated-MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells. (E) Expressions of cleaved caspase family members in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under GNE-6776 treatment, by western blotting analysis with specific antibodies. (F) Levels of MMP in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under serial doses of GNE-6776, assessed using flow cytometry assays. (G) Analysis of total depolarized levels of MMP in GNE-6776-treated MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells. (H) Expression of Bcl family members in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under serial doses of GNE-6776, by western blot analysis with specific antibodies. Data are represented as the mean ± SEM of biological triplicate experiments. * p < 0.05, compared with cells with steady concentration of doxorubicin and paclitaxel, respectively.

Effect of USP7 inhibitor on cell viability of chemoresistant TNBC. (A) The cell viability in MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells treated with serial doses of USP7 inhibitor (GNE-6776) combined with doxorubicin or paclitaxel, respectively. (B) The cell viability of MDA-MB-231-DoxR (left) and MDA-MB-231-PtxR (right) cells treated with serial doses of USP7 inhibitor (GNE-6776). (C) Apoptotic levels in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under serial doses of GNE-6776 treatment, assessed performing Annexin V-dependent flow cytometry assays. (D) Analysis for apoptosis of GNE-6776 treated-MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells. (E) Expressions of cleaved caspase family members in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under GNE-6776 treatment, by western blotting analysis with specific antibodies. (F) Levels of MMP in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under serial doses of GNE-6776, assessed using flow cytometry assays. (G) Analysis of total depolarized levels of MMP in GNE-6776-treated MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells. (H) Expression of Bcl family members in MDA-MB-231-DoxR (upper) and MDA-MB-231-PtxR (lower) cells under serial doses of GNE-6776, by western blot analysis with specific antibodies. Data are represented as the mean ± SEM of biological triplicate experiments. * p < 0.05, compared with cells with steady concentration of doxorubicin and paclitaxel, respectively.